SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Unquoted Biotechs
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (10)8/24/2001 6:44:22 AM
From: nigel bates  Read Replies (1) of 253
 
Noticed Rigel deal with Sequitur on Genomeweb -
genomeweb.com
(also that ISIP are suing them...)

List of collaborators (& other stuff) from Sequitur website-

ANTISENSE FUNCTIONAL GENOMICS PROGRAM
Antisense technology can determine gene function and validate small molecule targets by specifically inhibiting gene expression in cell culture*. Sequitur's Antisense Functional Genomics Program offers high potency, high specificity 2nd generation antisense compounds. Our program is based on data from our in-house cellular screening (see Example page) and our staff of experts in the antisense field. 
Major advantages of our program include:

* Research rights to key dominating patents in the antisense field
* Collaborative research in our state-of-the-art cellular biology laboratory
* High activity at doses as low as 30nM
* Low toxicity reduced phosphorothioate and phosphorothioate-free compounds
* Target gene inhibition with only one to six compounds screened
* Proven technology;  Vassar et al., Science 286:735-41 (1999), Yan et al.,Nature 1999, 402:533-537
* Rapid results compared to other target validation technologies
* Optimized cellular delivery methods and reagents
* Flexible program options available with no downstream royalties
*  Leading scientists in the field of antisense technology

Our comprehensive corporate antisense subscription program provides access to Sequitur's current and newly developed antisense technology. By providing a complete antisense technology program, Sequitur allows the client to concentrate on the biological and clinical aspects of their research.    Clients and Collaborators include:

* Amgen
* Agouron
* Bristol-Meyers Squibb
* Genentech
* Genome Therapeutics
* Glaxo Wellcome
* Harvard University
* Incyte Genomics
* Millennium Pharmaceuticals
* Mayo Clinic
* Pfizer 
* Pharmacia
* Proctor and Gamble
* Rigel
* Scripps Research Institute
* Smith-Kline Beecham
* Vertex
* Wyeth-Ayerst
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News